Abstract：
BACKGROUND: Neuroendocrine neoplasms (NENs) are classified as neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and mixed neuroendocrine and nonneuroendocrine neoplasms (MiNENs) according to World Health Organization classification. We present our experience of NENs of the gallbladder (GB) from a high-volume cancer hospital.
METHODS: The present study is a retrospective analysis of all patients with GB NENs who presented between January 2015 and June 2023. The patient details and treatment received with follow-up were noted. The primary endpoint was overall survival (OS).
RESULTS: A total of 147 patients were included in the study. The median age was 52 (27-81) years. There was a female predominance (70.7%). NEC was the most common subtype (84.4%) followed by MiNEN (12.9%) and NET (2.7%). The most common stage at presentation was metastatic (70.7%) followed by locally advanced (21.8%), and early disease (7.5%). The median follow-up was 9.92 (1.77-76.06) months. Median OS was 6.14 (3.93-8.35) months. Median OS in patients who received multimodality treatment was 20.20 (17.99-22.41) months versus 4.00 (2.91-5.10) months in those who did not receive it.
CONCLUSIONS: GB NENs are rare, but aggressive tumors with NEC being the most common type. Multimodality treatment yields favorable outcomes. However, the development of better systemic therapy is needed to help improve survival further.
METHODS: The present study is a retrospective analysis of all patients with GB NENs who presented between January 2015 and June 2023. The patient details and treatment received with follow-up were noted. The primary endpoint was overall survival (OS).
RESULTS: A total of 147 patients were included in the study. The median age was 52 (27-81) years. There was a female predominance (70.7%). NEC was the most common subtype (84.4%) followed by MiNEN (12.9%) and NET (2.7%). The most common stage at presentation was metastatic (70.7%) followed by locally advanced (21.8%), and early disease (7.5%). The median follow-up was 9.92 (1.77-76.06) months. Median OS was 6.14 (3.93-8.35) months. Median OS in patients who received multimodality treatment was 20.20 (17.99-22.41) months versus 4.00 (2.91-5.10) months in those who did not receive it.
CONCLUSIONS: GB NENs are rare, but aggressive tumors with NEC being the most common type. Multimodality treatment yields favorable outcomes. However, the development of better systemic therapy is needed to help improve survival further.
摘要：
背景：神经内分泌肿瘤（NENs）被归类为神经内分泌肿瘤（NETs），神经内分泌癌，和根据世界卫生组织分类的混合性神经内分泌和非神经内分泌肿瘤(MINENs)。我们介绍了一家高容量癌症医院的胆囊NEN（GB）经验。
方法：本研究是对2015年1月至2023年6月期间所有GBNENs患者的回顾性分析。记录了患者的详细信息和随访中接受的治疗。主要终点是总生存期（OS）。
结果：共有147名患者被纳入研究。中位年龄为52（27-81）岁。女性占主导地位（70.7%）。NEC是最常见的亚型（84.4%），其次是MiNEN（12.9%）和NET（2.7%）。最常见的分期是转移性（70.7%），其次是局部晚期（21.8%）。早期疾病（7.5%）。中位随访时间为9.92(1.77-76.06)个月。中位OS为6.14(3.93-8.35)个月。接受多模式治疗的患者的中位OS为20.20（17.99-22.41）个月，而未接受治疗的患者为4.00（2.91-5.10）个月。
结论：GBNEN很少见，但NEC是最常见的侵袭性肿瘤。多模态治疗产生有利的结果。然而,需要开发更好的系统疗法来帮助进一步提高生存率.
方法：本研究是对2015年1月至2023年6月期间所有GBNENs患者的回顾性分析。记录了患者的详细信息和随访中接受的治疗。主要终点是总生存期（OS）。
结果：共有147名患者被纳入研究。中位年龄为52（27-81）岁。女性占主导地位（70.7%）。NEC是最常见的亚型（84.4%），其次是MiNEN（12.9%）和NET（2.7%）。最常见的分期是转移性（70.7%），其次是局部晚期（21.8%）。早期疾病（7.5%）。中位随访时间为9.92(1.77-76.06)个月。中位OS为6.14(3.93-8.35)个月。接受多模式治疗的患者的中位OS为20.20（17.99-22.41）个月，而未接受治疗的患者为4.00（2.91-5.10）个月。
结论：GBNEN很少见，但NEC是最常见的侵袭性肿瘤。多模态治疗产生有利的结果。然而,需要开发更好的系统疗法来帮助进一步提高生存率.
